Drugmaker Novo Nordisk warns U.S. legislation could make business difficult

COPENHAGEN (Reuters) - Drugmaker Novo Nordisk said on Wednesday that new legislation being prepared in some U.S. states to improve pricing transparency could potentially impact business in its key market.

Drugmaker Novo Nordisk warns U.S. legislation could make business difficult
Read More


Bagikan Berita Ini